NAVEGA THERAPEUTICS
Navega Therapeutics is a preclinical stage company pursuing a radically different approach to treat chronic pain and tackle the opioid epidemic. At Navega, we have developed a novel gene therapy to treat severe chronic pain that is non-addictive, highly specific, and long lasting. We were inspired by nature: there are humans that have a mutation in their genome that feel no pain whatsoever. We have imitated this process by developing a novel gene therapy to target pain in a non-addictive way. I... n our proof of concept, we demonstrated that the mice that received our therapy have an increased pain tolerance and lower pain levels during weeks. We validated our approach in three preclinical animal models: inflammatory pain, chemotherapy-induced neuropathic pain and BzATP-induced pain. We also have safety studies demonstrating that our therapy has no neurological, motor, or olfactory side-effects. We have been awarded two SBIR grants, one from the National Cancer Institute and another one from the National Institute of Neurological Disorders and Stroke, and licensed three patents from UCSD.
NAVEGA THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Health Care Neuroscience Therapeutics
Founded:
2018-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.navegatx.com
Total Employee:
1+
Status:
Active
Contact:
(858) 729-8345
Email Addresses:
[email protected]
Total Funding:
6.69 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Google Tag Manager Nginx Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Bicara Therapeutics
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Trefoil Therapeutics
Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell mediated diseases.
Current Employees Featured
Founder
Investors List
National Cancer Institute
National Cancer Institute investment in Grant - Navega Therapeutics
National Institute of Neurological Disorders and Stroke
National Institute of Neurological Disorders and Stroke investment in Grant - Navega Therapeutics
Creative Destruction Lab (CDL)
Creative Destruction Lab (CDL) investment in Non Equity Assistance - Navega Therapeutics
National Cancer Institute
National Cancer Institute investment in Grant - Navega Therapeutics
National Institute of Neurological Disorders and Stroke
National Institute of Neurological Disorders and Stroke investment in Grant - Navega Therapeutics
Newest Events participated
Participated in Biotech Showcase: Investor and Partnering Conference in San Francisco
on 2022-01-12 as speaker
Official Site Inspections
http://www.navegatx.com
- Host name: fatcobra.introbay.com
- IP address: 88.99.210.16
- Location: Morlenbach Germany
- Latitude: 49.5992
- Longitude: 8.7347
- Timezone: Europe/Berlin
- Postal: 69509
More informations about "Navega Therapeutics"
Navega Therapeutics | Gene Therapies for Chronic Pain and …
Harnessing the precision of zinc-finger and CRISPR based epigenome regulation to enable next-generation gene therapies. We use cookies to ensure that we give you the best experience on …See details»
Senior Research Associate | Navega Therapeutics
Sep 2, 2021 · Navega is looking for a highly motivated individual to join our Erythromelalgia program as a Senior Research Associate. The ideal candidate will have broad cell and …See details»
Navega Therapeutics - Crunchbase Company Profile
Navega Therapeutics is a preclinical stage company developing epigenetic gene therapies for neurological and ophthalmic diseases. View contacts for Navega Therapeutics to access new leads and connect with decision-makers.See details»
Navega Therapeutics - LinkedIn
By leveraging cutting-edge AI-enabled epigenetic tools to suppress the genes responsible for chronic pain, Navega Therapeutics is at the forefront of developing these next-generation pain...See details»
Navega Therapeutics Company Profile 2024: Valuation, Funding ...
Developer of gene therapies designed to treat chronic pain and tackle the opioid epidemic. The company's therapies target pain that is non-addictive, highly specific, and long-lasting, …See details»
NAVEGA THERAPEUTICS, INC. - VentureRadar
Website: http://www.navegatx.com Develops epigenetic-regulation gene therapies for common diseases, harnessing the epigenome to modify gene expression and treat challenging …See details»
Tales of a Startup: Navega Therapeutics - University of …
May 28, 2021 · Navega Therapeutics is answering those pains with a CRISPR epigenetic gene-therapy tool, helping to deliver long-lasting pain relief without the risk of addiction associated with prescription opioid drugs. The company has …See details»
NAVEGA THERAPEUTICS, INC. | VentureRadar
Website: http://www.navegatx.com. Develops gene therapy using CRISPR/dCas9 and zinc-fingers to target NaV1.7, aiming for non-permanent, specific pain relief via AAV delivery. …See details»
Scientist position | Navega Therapeutics
Sep 2, 2021 · Navega Therapeutics is a preclinical stage company developing epigenetic-regulation gene therapies to tackle common diseases. Instead of editing the genome, Navega is harnessing the power of the epigenome to …See details»
Charles River and Navega Therapeutics Announce Comprehensive …
Mar 14, 2024 · Navega is a preclinical stage company developing epigenetic-regulation gene therapies to tackle common and complex diseases via a proprietary AI-enabled zinc finger …See details»
Navega Therapeutics becomes a trusted partner of the HEAL …
Sep 26, 2019 · Navega Therapeutics aims to develop a non-addictive gene therapy for chronic pain, to improve the current paradigm of pain treatment.See details»
Navega Therapeutics – H+
Founded in 2018, Navega Therapeutics Inc. is a preclinical stage company pursuing a radically different approach to treat chronic pain and tackle the opioid epidemic. Our gene therapy …See details»
Navega Therapeutics - Overview, News & Similar companies
Navega Therapeutics contact info: Phone number: (928) 750-1629 Website: www.navegatx.com What does Navega Therapeutics do? About Navega Therapeutics Inc. | Navega is a …See details»
Stephen Waxman MD, PhD | Navega Therapeutics
Dr. Waxman is the Bridget Flaherty Professor of Neurology, Neurobiology, and Pharmacology, and the founder and director of the Neuroscience & Regeneration Research Center at Yale …See details»
Award - SBIR
Based on our preclinical data in rodents, Navega Therapeutics’ proposal aims to optimize a gene therapy for chronic pain in human cell lines and human dorsal root ganglion neurons.See details»
‪Ana M Moreno‬ - ‪Google Scholar‬
Verified email at navegatx.com. Nathan M. Palmer PhD Candidate Computational Social Science, George Mason University ... Translational Vectorology, CMRI, Westmead, Australia Verified …See details»
Navega Therapeutics has been recognized as a TechConnect …
Sep 15, 2019 · Navega Therapeutics has been recognized as a 2019 TechConnect Defense Innovation Awardee at next month's DefenseTechConnect Summit and Expo in National …See details»
Gene therapies to reduce chronic pain: are we there yet?
We are in urgent need of new treatments for long-term pain management and gene therapies offer an attractive alternative approach based on the contribution of different genes to chronic …See details»
Blog | Navega Therapeutics
Navega Therapeutics Announces a Collaborative Research Agreement with the NIH's National Center for Advancing Translational Sciences (NCATS) as part of the HEAL InitiativeSee details»